Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Lucosky Brookman Represents Kingswood Investments in Telomir Pharmaceuticals' Successful $7 Million IPO

Lucosky Brookman is pleased to announce its representation of Kingswood Investments, a division of Kingswood Capital Partners LLC, in Telomir Pharmaceuticals, Inc.'s (Nasdaq: TELO) recent initial public offering (IPO). Telomir Pharmaceuticals, a pre-clinical-stage pharmaceutical company pioneering the development and commercialization of Telomir-1, closed its IPO on February 9, 2024, marking a significant milestone for the company and its innovative approach to age reversal.

Telomir Pharmaceuticals offered 1,000,000 shares of common stock at a public offering price of $7.00 per share, resulting in gross proceeds of $7 million for the company, before underwriting discounts, commissions, and other offering expenses. All shares of common stock were offered by Telomir, symbolizing the company's commitment to fueling its growth and advancing its groundbreaking research in extending the DNA's protective telomere caps.

The successful IPO culminated in the commencement of trading on The Nasdaq Capital Market under the ticker symbol "TELO." This milestone event not only provides Telomir Pharmaceuticals with access to public capital markets but also underscores investor confidence in the company's innovative approach and potential to address age-related conditions.

Lucosky Brookman's representation of Kingswood Investments, acting as the sole book-running manager for the IPO, played a pivotal role in facilitating the transaction's smooth execution. Kingswood Investments, a division of Kingswood Capital Partners LLC, demonstrated its expertise and commitment to delivering value to its clients by guiding Telomir Pharmaceuticals through the intricacies of the IPO process.

Telomir Pharmaceuticals' mission to develop Telomir-1 as the first novel small molecule capable of lengthening DNA's telomere caps holds immense promise in the field of age reversal and longevity research. The company's commitment to advancing scientific breakthroughs aligns with its vision of revolutionizing healthcare and enhancing quality of life for individuals worldwide.

With the IPO proceeds, Telomir Pharmaceuticals is well-positioned to accelerate its research and development efforts, expand its pipeline, and pursue strategic initiatives to further solidify its leadership in the age reversal space. The company's innovative approach, coupled with strong investor support, sets the stage for continued growth and success in the years ahead.